HC Wainwright Has Bullish Forecast for ROIV FY2026 Earnings

Roivant Sciences Ltd. (NASDAQ:ROIV) – Analysts at HC Wainwright raised their FY2026 EPS estimates for Roivant Sciences in a note issued to investors on Tuesday, February 10th. HC Wainwright analyst D. Tsao now anticipates that the company will post earnings of ($1.55) per share for the year, up from their previous estimate of ($1.61). HC Wainwright currently has a “Buy” rating and a $33.00 target price on the stock. The consensus estimate for Roivant Sciences’ current full-year earnings is ($0.92) per share. HC Wainwright also issued estimates for Roivant Sciences’ Q1 2027 earnings at ($0.42) EPS, Q2 2027 earnings at ($0.46) EPS, Q3 2027 earnings at ($0.45) EPS, Q4 2027 earnings at ($0.46) EPS and FY2027 earnings at ($1.79) EPS.

Other equities analysts have also recently issued reports about the stock. Jefferies Financial Group reiterated a “buy” rating and issued a $30.00 target price on shares of Roivant Sciences in a research note on Monday. TD Cowen reiterated a “buy” rating on shares of Roivant Sciences in a research report on Saturday, February 7th. Leerink Partners raised their target price on Roivant Sciences from $29.00 to $32.00 and gave the company an “outperform” rating in a research report on Monday, December 15th. Guggenheim lifted their price target on Roivant Sciences from $28.00 to $30.00 and gave the company a “buy” rating in a research note on Monday. Finally, Weiss Ratings cut Roivant Sciences from a “hold (c-)” rating to a “sell (d)” rating in a report on Monday. One analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $28.69.

Roivant Sciences Stock Performance

NASDAQ ROIV opened at $26.45 on Friday. The firm has a market capitalization of $18.40 billion, a P/E ratio of -22.61 and a beta of 1.22. The stock has a 50-day simple moving average of $22.71 and a two-hundred day simple moving average of $18.31. Roivant Sciences has a fifty-two week low of $8.73 and a fifty-two week high of $27.94.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently modified their holdings of ROIV. UBS Group AG grew its holdings in shares of Roivant Sciences by 570.0% in the fourth quarter. UBS Group AG now owns 18,390,792 shares of the company’s stock valued at $399,080,000 after purchasing an additional 15,645,836 shares in the last quarter. Morgan Stanley lifted its holdings in Roivant Sciences by 31.7% during the 4th quarter. Morgan Stanley now owns 58,359,553 shares of the company’s stock worth $1,266,402,000 after buying an additional 14,036,696 shares in the last quarter. Goldman Sachs Group Inc. boosted its position in Roivant Sciences by 365.2% in the 4th quarter. Goldman Sachs Group Inc. now owns 10,982,633 shares of the company’s stock valued at $238,323,000 after buying an additional 8,621,567 shares during the period. Assenagon Asset Management S.A. grew its stake in shares of Roivant Sciences by 11,507.5% in the fourth quarter. Assenagon Asset Management S.A. now owns 6,937,112 shares of the company’s stock worth $150,535,000 after acquiring an additional 6,877,348 shares in the last quarter. Finally, Norges Bank acquired a new position in shares of Roivant Sciences in the fourth quarter worth $112,750,000. 64.76% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity

In other news, CFO Richard Pulik sold 406,731 shares of the stock in a transaction that occurred on Tuesday, December 23rd. The shares were sold at an average price of $22.43, for a total value of $9,122,976.33. Following the completion of the sale, the chief financial officer owned 239,413 shares of the company’s stock, valued at $5,370,033.59. This represents a 62.95% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, major shareholder Vivek Ramaswamy sold 1,975,858 shares of the firm’s stock in a transaction that occurred on Friday, December 12th. The stock was sold at an average price of $21.96, for a total transaction of $43,389,841.68. Following the sale, the insider owned 36,350,621 shares of the company’s stock, valued at $798,259,637.16. This represents a 5.16% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 11,957,664 shares of company stock valued at $265,756,784 in the last 90 days. 10.80% of the stock is owned by insiders.

Roivant Sciences News Summary

Here are the key news stories impacting Roivant Sciences this week:

• Positive Sentiment: Multiple analysts raised price targets and maintained bullish ratings (HC Wainwright, Goldman Sachs, Leerink, Citi — consensus PT ~ $28.69), supporting a positive headline narrative for the stock. MarketBeat ROIV coverage
• Positive Sentiment: Institutional flows show new and increased positions (several funds added ROIV, LPL Financial materially increased its stake), which can provide demand support below recent highs. MarketBeat institutional ownership report
• Neutral Sentiment: HC Wainwright slightly improved its FY2026 EPS view (less negative) and kept a Buy rating with a $33 target — this is mixed for stock moves because estimates remain negative even as the price target was raised. HC Wainwright note
• Negative Sentiment: Director Daniel Allen Gold sold two large blocks (425,000 shares on Feb 11 and 375,784 shares on Feb 13) at ~ $26.50 per share (SEC filing). Large director sales can create near‑term selling pressure and raise investor caution. SEC filing — Daniel Gold sales
• Negative Sentiment: Insider Mayukh Sukhatme sold 339,441 shares on Feb 9 at ~$26.47; this is another sizable insider disposition following previous large sales, which may weigh on sentiment. InsiderTrades / sale report
• Negative Sentiment: HC Wainwright cut several 2027 quarterly EPS forecasts and lowered FY2027 EPS materially (from about -$1.22 to -$1.79), signaling expectations for weaker near‑term financial performance — a clear negative for sentiment until operational catalysts emerge. HC Wainwright estimate update

Roivant Sciences Company Profile

Roivant Sciences is a biopharmaceutical company focused on the development and commercialization of innovative therapies through a network of subsidiary businesses known as “Vants.” Founded in 2014, Roivant acquires or in-licenses clinical-stage assets that have progressed beyond proof of concept and seeks to advance them efficiently toward regulatory approval. By organizing each program into a dedicated subsidiary, the company aims to streamline decision-making, allocate resources more effectively, and accelerate development timelines.

The core activities of Roivant involve identifying promising drug candidates across a range of therapeutic areas, including neurology, rare diseases, immunology, oncology, and women’s health.